Venlafaxine and GAD

NEW YORK, June 21 (Praxis Press) Generalized anxiety disorder (GAD) is associated with debilitating psychic and somatic symptoms. Previous studies have found that Venlafaxine extended-release (XR) capsules are effective in short-term treatment of patients with GAD, but without major depressive disorder (MDD). It is unclear, however, whether venlafaxine XR confers long-term benefits. Gelenberg and colleagues compared the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in 251 o

June 21, 2000

NEW YORK, June 21 (Praxis Press) Generalized anxiety disorder (GAD) is associated with debilitating psychic and somatic symptoms. Previous studies have found that Venlafaxine extended-release (XR) capsules are effective in short-term treatment of patients with GAD, but without major depressive disorder (MDD). It is unclear, however, whether venlafaxine XR confers long-term benefits. Gelenberg and colleagues compared the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in 251 outpatients with GAD, without associated MDD, and compared them to controls taking a placebo (see article). During weeks 6 through 28 of the trial, response rates to standardized tests measuring anxiety in the venlafaxine XR group were 69% or higher compared with rates of 42% to 46% in the placebo group. The most common side effects were nausea, followed by somnolence and dry mouth. Venlafaxine XR is an effective, rapidly acting, safe, once-daily agent for both the short- and long-term treatment of anxiety.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech